A technical revolution has quietly changed the landscape of organ donation in the United States. Over the last 25 years, the proportion of organs recovered after circulatory death—when the heart stops—has increased from 2% to 49%, according to new research from NYU Langone Health and NYU Grossman School of Medicine published in the Journal of the American Medical Association (JAMA) recently. 

The statistics represent a structural shift in how the United States determines donor viability. Approximately 100,000 Americans are now on transplant waiting lists. For decades, the system relied heavily on donors who had been deemed brain dead, even if their hearts were still beating on ventilators. Patients with stopped hearts were mostly ruled out. That standard has now been overturned. 

According to researchers, organs that were once considered "unusable"—from older donors, those with a higher BMI, or those with diabetes and other chronic illnesses—now make up a significant and growing portion of the donor pool. Advances in organ preservation technologies, including machine and normothermic perfusion systems, have made a difference. 

The distinction is clinical and important. Brain death is defined as the permanent loss of all brain function when circulation is artificially maintained. Circulatory death occurs when the heart stops pumping and blood flow quits. Historically, organs that were deprived of oxygenated blood were deemed too damaged for transplantation. 

Perfusion technology has altered that equation. Normothermic perfusion devices deliver warm, oxygenated blood or preservation solution to organs outside the body, essentially resuscitating them. Machine perfusion systems can keep livers, kidneys, and other organs alive long enough to assess their viability and minimise harm prior to transplantation. In consequence, technology has expanded the biological clock. 

The results are measurable. Donation after circulatory death (DCD) currently accounts for nearly half of all organ donors in the United States, up roughly 25-fold from 2% a generation ago. For a country trying to reduce the supply-demand gap in transplantation, the expansion represents one of the most substantial capacity gains in years. 

The transition is, however, uneven. The Organ Procurement and Transplantation Network (OPTN) data, referenced in the NYU study, show significant geographic discrepancies across the nation's 55 organ procurement organisations (OPOs). In some locations, DCD donors account for only 11% of recoveries. In some cases, the figure approaches 73%. 

This range has effectively produced what experts refer to as a "transplant lottery", in which access to cutting-edge healing treatments is primarily dependent on geography rather than medical need. 

According to NYU Grossman investigators, the variation points to the urgent need for standardised practices and increased openness. They emphasise that widespread implementation of DCD techniques necessitates uniform clinical guidelines, more training, and public education about circulatory death donations. Without coordination across OPOs, the system risks entrenching imbalances even as overall donor numbers increase. 

The stakes go beyond statistics. In the United States, about 100,000 patients are still on the waiting list for organs, which is roughly similar to the population of Udaipur or Thanjavur. The technological advancement of DCD has begun to alleviate this load, but unequal application limits its full potential. 

The NYU researchers emphasise that a circulatory death donation is no longer an experiment. It has become important to the transplant system in the United States. However, its unequal reception implies that institutional inertia, logistical constraints, and regional practice differences continue to influence outcomes. 

The findings show a significant decline. They represent a paradigm shift in who can be an organ donor. The speed with which the remaining regions narrow the deficit will determine whether this change results in uniformly improved access across the country.